Connect Biopharma Hldgs Analyst Ratings
Connect Biopharma Hldgs Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/08/2023 | 488.24% | SVB Leerink | $9 → $7 | Maintains | Outperform |
| 06/02/2022 | 320.17% | Cantor Fitzgerald | → $5 | Initiates Coverage On | → Overweight |
| 05/05/2022 | 26.05% | Piper Sandler | $25 → $1.5 | Downgrades | Overweight → Neutral |
| 05/04/2022 | 656.3% | SVB Leerink | $22 → $9 | Maintains | Outperform |
| 01/06/2022 | 1748.74% | SVB Leerink | $32 → $22 | Maintains | Outperform |
| 07/02/2021 | 2168.91% | CICC | → $27 | Initiates Coverage On | → Outperform |
| 04/13/2021 | 2168.91% | Jefferies | → $27 | Initiates Coverage On | → Buy |
| 04/13/2021 | 2589.08% | SVB Leerink | → $32 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 02/08/2023 | 488.24% | SVB Leerink | $9→$7 | 維護 | 跑贏大盤 |
| 06/02/2022 | 320.17% | 康託·菲茨傑拉德 | →$5 | 開始承保 | →超重 |
| 05/05/2022 | 26.05% | 派珀·桑德勒 | $25→$1.5 | 評級下調 | 超重→中性 |
| 05/04/2022 | 656.3% | SVB Leerink | $22→$9 | 維護 | 跑贏大盤 |
| 01/06/2022 | 1748.74% | SVB Leerink | $32→$22 | 維護 | 跑贏大盤 |
| 07/02/2021 | 2168.91% | 中金公司 | →$27 | 開始承保 | →跑贏大盤 |
| 04/13/2021 | 2168.91% | 傑富瑞 | →$27 | 開始承保 | →購買 |
| 04/13/2021 | 2589.08% | SVB Leerink | →$32 | 開始承保 | →跑贏大盤 |
What is the target price for Connect Biopharma Hldgs (CNTB)?
康乃德生物的目標價是多少？
The latest price target for Connect Biopharma Hldgs (NASDAQ: CNTB) was reported by SVB Leerink on February 8, 2023. The analyst firm set a price target for $7.00 expecting CNTB to rise to within 12 months (a possible 488.24% upside). 4 analyst firms have reported ratings in the last year.
SVB Leerink於2023年2月8日報道了康乃德生物(納斯達克：CNTB)的最新目標價。這家分析公司將目標價定為7美元，預計CNTB將在12個月內上漲至(可能上漲488.24%)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Connect Biopharma Hldgs (CNTB)?
分析師對康乃德生物的最新評級是什麼？
The latest analyst rating for Connect Biopharma Hldgs (NASDAQ: CNTB) was provided by SVB Leerink, and Connect Biopharma Hldgs maintained their outperform rating.
康乃德生物(納斯達克股票代碼：CNTB)的最新分析師評級由SVB Leerink提供，康乃德生物Hldgs維持其表現優於大盤的評級。
When is the next analyst rating going to be posted or updated for Connect Biopharma Hldgs (CNTB)?
新浪康乃德生物的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Connect Biopharma Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Connect Biopharma Hldgs was filed on February 8, 2023 so you should expect the next rating to be made available sometime around February 8, 2024.
分析師們在進行了廣泛的研究後才得出股票評級，其中包括查閱公開的財務報表，與康乃德生物的高管和客戶交談，以及收聽財報電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。康乃德生物Hldgs的上一次評級是在2023年2月8日提交的，因此你應該預計下一次評級將在2024年2月8日左右公佈。
Is the Analyst Rating Connect Biopharma Hldgs (CNTB) correct?
分析師對新浪康乃德生物的評級正確嗎？
While ratings are subjective and will change, the latest Connect Biopharma Hldgs (CNTB) rating was a maintained with a price target of $9.00 to $7.00. The current price Connect Biopharma Hldgs (CNTB) is trading at is $1.19, which is out of the analyst's predicted range.
雖然評級是主觀的，會發生變化，但最新的康乃德生物Hldgs(CNTB)評級維持不變，目標價在9美元至7美元之間。康乃德生物目前的股價為1.19美元，超出了分析師的預測區間。